STOCK TITAN

Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Vanda Pharmaceuticals Inc. executive Christos Vasilios Mihael Polymeropoulos, Senior VP and Medical Director, filed an initial ownership report showing his equity positions in the company. He holds a stock option to buy 61,200 shares of common stock at an exercise price of $7.05 per share, expiring on February 15, 2033. The filing also lists multiple common stock and restricted stock unit (RSU) awards, with time-based vesting schedules running from March 1, 2027 through March 1, 2029, contingent on his continued employment and delivery of vested shares on the first permissible trading day after each vest date.

Positive

  • None.

Negative

  • None.
Insider Polymeropoulos Christos Vasilios Mihael
Role Senior VP, Medical Director
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 61,200 shares (Direct); Common Stock — 129,791 shares (Direct)
Footnotes (1)
  1. Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest in full on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through such vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Represents shares of common stock underlying an RSU award. One-half of the RSU will vest on March 1, 2027, and the remaining one-half of the RSU will vest on March 1, 2028, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest. Represents shares of common stock underlying an RSU award. The RSU vests as follows: 1/3 will vest on March 1, 2027, 1/3 will vest on March 1, 2028, and the remaining 1/3 will vest on March 1, 2029, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest. Represents shares of common stock underlying an RSU award. The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest. The option vests in equal monthly installments on the 16th day of each month through February 16, 2027, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
Stock option underlying shares 61,200 shares Right to buy Vanda common stock
Option exercise price $7.05/share Exercise price for 61,200-share option
Option expiration February 15, 2033 Expiration date of stock option position
Common stock holding line 129,791 shares Total common shares shown in one entry
RSU first vesting date March 1, 2027 Initial vest date across multiple RSU awards
Final RSU vesting date March 1, 2029 Last scheduled vesting under described RSU awards
restricted stock unit financial
"Represents shares of common stock underlying a time-based restricted stock unit award ("RSU")."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
First Permissible Trading Day financial
"Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement)"
continuous employment financial
"provided the Reporting Person remains continuously employed by the Issuer through such vesting date."
continuous service financial
"provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Polymeropoulos Christos Vasilios Mihael

(Last)(First)(Middle)
2200 PENNSYLVANIA AVENUE NW
SUITE 300E

(Street)
WASHINGTON DISTRICT OF COLUMBIA 20037

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026
3. Issuer Name and Ticker or Trading Symbol
Vanda Pharmaceuticals Inc. [ VNDA ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior VP, Medical Director
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock129,791D
Common Stock6,450(1)D
Common Stock50,000(2)D
Common Stock75,000(3)D
Common Stock125,000(4)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (5)02/15/2033Common Stock61,200$7.05D
Explanation of Responses:
1. Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest in full on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through such vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
2. Represents shares of common stock underlying an RSU award. One-half of the RSU will vest on March 1, 2027, and the remaining one-half of the RSU will vest on March 1, 2028, provided the Reporting Person remains continuously employed by the Issuer through each vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
3. Represents shares of common stock underlying an RSU award. The RSU vests as follows: 1/3 will vest on March 1, 2027, 1/3 will vest on March 1, 2028, and the remaining 1/3 will vest on March 1, 2029, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
4. Represents shares of common stock underlying an RSU award. The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest.
5. The option vests in equal monthly installments on the 16th day of each month through February 16, 2027, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
/s/ Christos Vasilios Mihael Polymeropoulos04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the VNDA Form 3 filing by Christos Polymeropoulos show?

The Form 3 shows Christos Polymeropoulos’ existing equity holdings in Vanda Pharmaceuticals, including common stock, stock options, and restricted stock units. It establishes his starting ownership position as Senior VP, Medical Director, without detailing any new purchase or sale transactions.

How many Vanda (VNDA) shares are covered by Christos Polymeropoulos’ stock option?

The filing lists a stock option covering 61,200 shares of Vanda common stock. This option gives him the right to buy those shares at a fixed exercise price, subject to the option’s vesting schedule and its stated expiration date in 2033.

What is the exercise price and expiration date of the VNDA stock option reported?

The stock option reported has an exercise price of $7.05 per share and expires on February 15, 2033. This means he may exercise the option at that price before expiration, subject to the vesting and continuous service conditions described.

What RSU vesting terms are disclosed for Vanda (VNDA) in this Form 3?

The footnotes describe several RSU awards that vest between March 1, 2027 and March 1, 2029. Some vest in a single installment, others in halves or thirds, all requiring continuous employment and delivering shares on the first permissible trading day after vesting.

Does the VNDA Form 3 indicate that shares are delivered immediately on RSU vesting?

Shares from RSU awards are delivered on the “First Permissible Trading Day” after vesting. This term, defined in the RSU agreement, ensures actual share delivery occurs only when trading is allowed under company and regulatory trading restrictions.